Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Appointed director

AN2 Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 4 Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Sold 83,337 shares @ $16.28, valued at $1.4M
Sold 15,764 shares @ $16.28, valued at $256.6k
Sold 4,770 shares @ $16.07, valued at $76.7k
Sold 902 shares @ $16.07, valued at $14.5k
10/03/2023 4 Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Sold 83,337 shares @ $16.28, valued at $1.4M
Sold 15,764 shares @ $16.28, valued at $256.6k
Sold 4,770 shares @ $16.07, valued at $76.7k
Sold 902 shares @ $16.07, valued at $14.5k
10/02/2023 144 Form 144 - Report of proposed sale of securities:
09/29/2023 4 Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Sold 707 shares @ $16.07, valued at $11.4k
Sold 134 shares @ $16.07, valued at $2.2k
Sold 7,160 shares @ $16.11, valued at $115.3k
Sold 1,356 shares @ $16.11, valued at $21.8k
09/29/2023 4 Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Sold 707 shares @ $16.07, valued at $11.4k
Sold 134 shares @ $16.07, valued at $2.2k
Sold 7,160 shares @ $16.11, valued at $115.3k
Sold 1,356 shares @ $16.11, valued at $21.8k
09/29/2023 144 Form 144 - Report of proposed sale of securities:
08/25/2023 4 Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Sold 336 shares @ $16, valued at $5.4k
Sold 64 shares @ $16, valued at $1k
08/25/2023 4 Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Sold 336 shares @ $16, valued at $5.4k
Sold 64 shares @ $16, valued at $1k
08/23/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 4 RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Bought 1,777,778 shares @ $9, valued at $16M
08/16/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/16/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, between the Company, Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C.",
"Opinion of Cooley LLP",
"AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock Menlo Park, CA - August 15, 2023 - AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of an underwritten offering of 7,777,778 shares of its common stock. The shares of common stock are being sold at a price of $9.00 per share, a premium from today's closing price. Investors who have agreed to purchase shares in the offering include RA Capital Management, TCGX, Frazier Life Sciences, Marshall Wace, Adage Capital Partners LP, Avidity Partners, Janus Henderson Investors and Surveyor Capital . The gross proceeds from the offering to AN2 are expected to be..."
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights Sufficient patients in screening expected to complete enrollment in Phase 2 portion of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex lung disease Expected initiation of Phase 3 portion of pivotal Phase 2/3 study in September Menlo Park, CA – August 10, 2023 – AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended June 30, 2023. “We’re pleased with the accelerated pace of enrollment in our pivotal Phase 2/3 study evaluating epetraborole for treatment-refractory MAC lung disease and b..."
07/25/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/05/2023 SC 13G JANUS HENDERSON GROUP PLC reports a 5.1% stake in AN2 Therapeutics, Inc.
06/09/2023 4 Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Granted 23,742 options to buy @ $5.91, valued at $140.3k
06/09/2023 4 Zakrzewski Joseph S (Director) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Granted 23,742 options to buy @ $5.91, valued at $140.3k
06/09/2023 4 FitzPatrick Margaret M (Director) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Granted 23,742 options to buy @ $5.91, valued at $140.3k
06/09/2023 4 Wong Stephanie (Director) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Granted 23,742 options to buy @ $5.91, valued at $140.3k
06/09/2023 4 Marks Gilbert Lynn (Director) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Granted 23,742 options to buy @ $5.91, valued at $140.3k
06/09/2023 4 Martin Patricia A. (Director) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Granted 23,742 options to buy @ $5.91, valued at $140.3k
06/09/2023 4 Spigelman Melvin K (Director) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Granted 23,742 options to buy @ $5.91, valued at $140.3k
06/09/2023 4 Readnour Robin Shane (Director) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Granted 23,742 options to buy @ $5.91, valued at $140.3k
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/15/2023 4 Easom Eric (CEO) has filed a Form 4 on AN2 Therapeutics, Inc.
Txns: Bought 10,000 shares @ $5.377, valued at $53.8k
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights • Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex lung disease Menlo Park, CA – May 11, 2023 – AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2023. “In the first quarter we continued to advance our pivotal Phase 2/3 trial evaluating epetraborole for treatment-refractory MAC lung disease with a total of nearly 80 clinical sites active worldwide. We are pleased with the momentum we’re seeing in the Asia-Pacific region, particula..."
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/13/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/29/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy